Potential of survivin for treatment of gynaecological tumour diseases

Czech version

Authors: D. Braný ^1,2; D. Dvorská ^1,2; E. Kúdela ²; Z. Danková ³; E. Halášová ¹; J. Višňovský ²
Authors‘ workplace: Divízia Molekulová Medicína, Martinské centrum pre biomedicínu JLF UK, Martin, riaditeľka divízie prof. RNDr. E. Halašová, PhD. ¹; Gynekologicko-pôrodnícka klinika JLF UK a UNM, Martin, prednosta prof. MUDr. J. Danko, CSc. ²; Divízia Onkológia, Martinské centrum pre biomedicínu JLF UK, Martin,  riaditeľka divízie doc. RNDr. Z. Lasabová, PhD. ³
Published in: Ceska Gynekol 2018; 83(3): 226-231

Overview

Objective:

The main purpose of this article is to consolidate known facts about survivin, its contribution to inhibition of apoptosis, impact to tumorigenesis of gynaecological types of tumours. and possibilities of inhibition of survivin on molecular-genetic levels.

Design:

A review article.

Settings:

Division of Molecular Medicine, Biomedical Center in Martin, JLF UK Martin, Slovakia; Department of Gynaecology and Obstetrics JLF UK and UNM Martin, Slovakia; Division of Oncology, Biomedical Center, JLF UK Martin, Slovakia.

Methods:

An analysis of the literature using database search engines focused on aberations in fuction of survivin, primarily in case of gynaecological tumours and possibilities of its inhibition.

Results and conclusions:

Survivin is the smallest member of inhibitor of apoptosis (IAP) family. Despite of its size and affiliation to mentioned gene family, survivin can affect besides inhibition of apoptosis also proper process of mitosis, DNA reparation and angiogenesis. High levels of survivin expression are typical for fetal tissues during intrauterine developement. In healthy, adult tissues remain levels of survivin very low. Nonetheless, abundant expression of survivin is in many cases typical for various types of cancer, including gynaecologycal cancers Generally, it is possible to associate higher amounts of survivin with poor prognosis and resistance to chemo- or radiotherapy.

Keywords:

survivin, BIRC5, gynaecological tumours, apoptosis, inhibition

Sources

1. Adams, JM., Cory, S. Life-or-death decisions by the Bcl-2 protein family. Trends Biochem Sci, 2001, 26, 1, p. 61–66.

2. Altieri, DC. New wirings in the survivin networks. Oncogene, 2008, 27, 48, p. 6276–6284.

3. Arend, RC., Londoño-Joshi, AI., Straughn, JM., et al. The Wnt/β-catenin pathway in ovarian cancer: a review. Gynecol Oncol, 2013, 131, 3, p. 772–779.

4. Athanassiadou, P., Grapsa, D., Athanassiades, P., et al. The prognostic significance of COX-2 and survivin expression in ovarian cancer. Pathology-Res Pract, 2008, 204, 4, p. 241–249.

5. Baalbergen, A., Molijn, AC., Quint, WG., et al. Conservative treatment seems the best choice in adenocarcinoma in situ of the cervix uteri. J lower genital Tract Dis, 2015, 19, 3, p. 239–243.

6. Cryns, V., Yuan, J. Proteases to die for. Genes Dev, 1998, 12, p. 1551–1570.

7. de Moraes, GN., Vasconcelos, FC., Delbue, D., et al. Doxorubicin induces cell death in breast cancer cells regardless of survivin and XIAP expression levels. Eur J Cell Biol, 2013, 92, 8, p. 247–256.

8. Dziegielewska, B., Casarez, EV., Yang, WZ., et al. T-type Ca2+ channel inhibitors sensitize ovarian cancer to carboplatin through downregulation of survivin gene expression. Cancer Res, 2015, 75, p. 5407–5407.

9. Ferrandina, G., Legge, F., Martinelli, E., et al. Survivin expression in ovarian cancer and its correlation with clinico-pathological, surgical and apoptosis-related parameters. Br J Cancer, 2005, 92, 2, p. 271–277.

10. Fukuda, S., Pelus, LM. Survivin, a cancer target with an emerging role in normal adult tissues. Mol Cancer Ther, 2006, 5, 5, p. 1087–1098.

11. Ganesh, S., Iyer, AK., Weiler, J., et al. Combination of siRNAdirected gene silencing with cisplatin reverses drug resistance in human nonsmall cell lung cancer. Mol Ther Nucleic Acids, 2013, 2, 7, p. e110.

12. Giaccone, G., Zatloukal, P., Roubec, J., et al. Multicenter phase II trial of YM155, a small molecule suppressor of survivin, in patients with advanced, refractory, nonsmallcell lung. Oncology, 2009, 27, 27, p. 4481–4486.

13. Glienke, W., Maute, L., Wicht, J., et al. Curcumin inhibits constitutive STAT3 phosphorylation in human pancreatic cancer cell lines and downregulation of survivin/BIRC5 gene expression. Cancer Investig, 2010, 28, 2, p. 166–171.

14. Hansen, JB., Fisker, N., Westergaard, M., et al. SPC3042, p. a proapoptotic survivin inhibitor. Molecular Cancer Ther, 2008, 7, 9, p. 2736–2745.

15. Hayashibara, T., Yamada, Y., Nakayama, S., et al. Resveratrol induces downregulation in survivin expression and apoptosis in HTLV-1-infected cell lines, p. a prospective agent for adult T cell leukemia chemotherapy. Nutr Cancer, 2002, 44, 2, p. 193–201.

16. Huser, M., Crha, I., Žáková J., et al. Proces reprodukčního stárnutí ženy – jeho příčiny a možnosti ovlivnění v praxi. Čes Gynek, 2010, 75, 4, s. 353–358.

17. Chen, L., Liang, L., Yan, X., et al. Survivin status affects prognosis and chemosensitivity in epithelial ovarian cancer. Intern J Gynecol Cancer, 2013, 23, 2, p. 256–263.

18. Chen, W., Zhong, X., Wei, Y., et al. TGF-β regulates survivin to affect cell cycle and the expression of EGFR and MMP9 in glioblastoma. Molecular Neurobiol, 2016, 53, 3, p. 1648–1653.

19. Chuwa, AH., Sone, K., Oda, K., et al. Significance of survivin as a prognostic factor and a therapeutic target in endometrial cancer. Gynecol Oncol, 2016, 141, 3, p. 564–569.

20. Jacquemin, G., Granci, V., Gallouet, AS., et al. Quercetin-mediated Mcl-1 and survivin downregulation restores TRAIL-induced apoptosis in non-Hodgkin‘s lymphoma B cells. Haematologica, 2012, 97, 1, p. 38–46.

21. Kobayashi, H., Uekuri, C., Akasaka, J., et al. The biology of uterine sarcomas: a review and update. Molecular Clin Oncol, 2013, 1, 4, p. 599–609.

22. Lewis, KD., Samlowski, W., Ward, J., et al. A multi-center phase II evaluation of the small molecule survivin suppressor YM155 in patients with unresectable stage III or IV melanoma. Investig New Drugs, 2011, 29, 1, p. 161–166.

23. Li, L., Gao, Y., Zhang, Z., et al. Silibinin inhibits cell growth and induces apoptosis by caspase activation, down-regulating survivin and blocking EGFR-ERK activation in renal cell carcinoma. Cancer Lett, 2008, 272, 1, p. 61–69.

24. Li, Z., Ren, W., Zeng, Q., et al. Effects of survivin on angiogenesis in vivo and in vitro. Amer J Translational Res, 2016, 8, 2, p. 270.

25. Ling, X., Cao, SS., Cheng, QY., et al. A novel small molecule FL118 that selectively inhibits survivin, Mcl-1, XIAP and cIAP2 in a p53-independent manner, shows superior antitumor activity. PLoS One, 2012, 7, 9, p. e45571.

26. Liu, T., Brouha, B., Grossman, D. Rapid induction of mitochondrial events and caspase-independent apoptosis in survivin-targeted melanoma cells. Oncogene, 2004, 23, 1, p. 39–48.

27. Lu, D., Qian, J., Yin, X., et al. Expression of PTEN and survivin in cervical cancer: promising biological markers for early diagnosis and prognostic evaluation. Brit J Biomed Sci, 2012, 69, 4, p. 143.

28. Mackenzie, GG., Queisser, N., Wolfson, ML., et al. Curcumin induces cell-arrest and apoptosis in association with the inhibition of constitutively active NF-kappaB and STAT3 pathways in Hodgkin‘s lymphoma cells. Int J Cancer, 2008, 123, 1, p. 56–65.

29. Nakahara, T., Kita, A., Yamanaka, K., et al. YM155, a novel small-molecule survivin suppressant, induces regression of established human hormone-refractory prostate tumor xenografts. Cancer Res, 2007, 67, 17, p. 8014–8021.

30. Necochea-Campion, R., Chen, CS., Mirshahidi, S., et al. Clinico-pathologic relevance of survivin splice variant expression in cancer. Cancer Lett, 2013, 339, 2, p. 167–174.

31. Saleem, M., Qadir, MI., Perveen, N., et al. Inhibitors of apoptotic proteins: new targets for anticancer therapy. Chem Biol Drug Design, 2013, 82, 3, p. 243–251.

32. Sankpal, UT., Ingersoll, SB., Shukoor, MI., et al. Expression of Sp1 and survivin in ovarian cancer specimens: potential novel therapeutic targets in disease treatment. Cancer Res, 2013, 73, p. 2159–2159.

33. Shi, X., Wang, D., Ding, K., et al. GDP366, a novel small molecule dual inhibitor of survivin and Op18, induces cell growth inhibition, cellular senescence and mitotic catastrophe in human cancer cells. Cancer Biol Ther, 2010, 9, 8, p. 640–650.

34. Shu, SR., Luo, X., Song, WX., et al. Ultra-structure changes and survivin expression in uterine fibroids after radiofrequency ablation. Intern J Hyperthermia, 2015, 31, 8, p. 896–899.

35. Sláma, J. Současné limity prevence karcinomu děložního hrdla v České republice. Čes Gynek, 2017, 82, 6, s. 482–486.

36. Song, Z., Xuebiao, Y., Wu, M. Direct interaction between survivin and Smac/DIABLO is essential for the anti-apoptotic activity of survivin during taxol-induced apoptosis. J Biol Chem, 2003, 278, 25, p. 23130–23140.

37. Suzuki, A., Ito, T., Kawano, H., et al. Survivin initiates procaspase 3/p21 complex formation as a result of interaction with Cdk4 to resist Fas-mediated cell death. Oncogene, 2000, 19, 10, p. 1346–1353.

38. Špaček, J., Laco, J., Petera, J., et al. Prognostické faktory u mezenchymálních a smíšených nádorů děložního těla. Čes Gynek, 2009, 74, 4, s. 292–297.

39. Tamm, I., Wang, Y., Sausville, E., et al. IAP-family protein survivin inhibits caspase activity and apoptosis induced by Fas [CD95], Bax, caspases, and anticancer drugs. Cancer Res, 1998, 58, 23, p. 5315–5320.

40. Tanioka, M., Nokihara, H., Yamamoto, N., et al. Phase I study of LY2181308, an antisense oligonucleotide against survivin, in patients with advanced solid tumors. Cancer Chemother Pharmacol, 2011, 68, 2, p. 505–511.

41. Vanderstraeten, A., Everaert, T., Van Bree, R., et al. In vitro validation of survivin as target tumor-associated antigen for immunotherapy in uterine cancer. J Immunother, 2015, 38, 6, p. 239–249.

42. Végran, F., Boidot, R., Oudin, C., et al. Association of p53 gene alterations with the expression of antiapoptotic survivin splice variants in breast cancer p53 alterations and antiapoptotic survivin variants. Oncogene, 2007, 26, 2, p. 290e7.

43. Véquaud, E., Desplanques, G., Jézéquel, P., et al. Survivin contributes to DNA repair by homologous recombination in breast cancer cells. Breast Cancer Res Treat, 2016, 155, 1, p. 53–63.

44. Walker, KM., Padhiar, AA. CR-NCI-EORTC-21st international symposium. Molecular targets and cancer therapeutics. Drugs J, 2013, 13, 1, p. 7–9.

45. Watson, JL., Greenshields, A., Hill, R., et al. Curcumin-induced apoptosis in ovarian carcinoma cells is p53-independent and involves p38 mitogen-activated protein kinase activation and downregulation of Bcl-2 and survivin expression and Akt signaling. Mol Carcinog, 2010, 49, 1, p. 13–24.

46. Wiechno, P., Somer, BG., Mellado, B., et al. A randomised phase 2 study combining LY2181308 sodium (survivin antisense oligonucleotide) with first-line docetaxel/prednisone in patients with castration-resistant prostate cancer. Eur Urol, 2014, 65, 3, p. 516–520.

47. Yoshida, H., Sumi, T., Hyun, Y., et al. Expression of survivin and matrix metalloproteinases in adenocarcinoma and squamous cell carcinoma of the uterine cervix. Oncol Reports, 2003, 10, 1, p. 45–49.

48. Zaffaroni, N., Pennati, M., Colella, G., et al. Expression of the anti-apoptotic gene survivin correlates with taxol resistance in human ovarian cancer. CMLS, 2002, 59, 8, p. 1406–1412.

49. Zikán, J., Pinkavová I., Sláma, J., et al. Molekulární charakteristiky borderline ovariálních tumorů ve vztahu k biologickému chování nádorů. Čes Gynek, 2009, 74, 6, s. 427–430.

50. Zhou, WQ., Sheng, QY., Sheng, YH., et al. Expressions of survivin, P16 (INK4a), COX-2, and Ki-67 in cervical cancer progression reveal the potential clinical application. Eur J Gynaecol Oncol, 2014, 36, 1, p. 62–68